Checkpoint Therapeutics, Inc. financial data

Symbol
CKPT on Nasdaq
Location
95 Sawyer Road, Suite 110, Waltham, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 30.3 % -28.9%
Debt-to-equity -143 % +17.6%
Return On Equity 292 % -17.4%
Return On Assets -673 % -41%
Operating Margin -50.6K %

Shares

Label TTM Value / Value Unit Change %
Common Stock, Shares, Outstanding 41.6M shares +142%
Entity Public Float 33.1M USD -53.7%
Weighted Average Number of Shares Outstanding, Basic 36.5M shares +133%
Weighted Average Number of Shares Outstanding, Diluted 36.5M shares +133%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 41K USD +32.3%
Research and Development Expense 26.8M USD -49.4%
General and Administrative Expense 8.8M USD -1.17%
Operating Income (Loss) -35.5M USD +42.4%
Nonoperating Income (Expense) -6.98M USD -336%
Net Income (Loss) Attributable to Parent -42.5M USD +27.6%
Earnings Per Share, Basic -1.74 USD/shares +68%
Earnings Per Share, Diluted -1.74 USD/shares +68%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 4.95M USD -33.3%
Other Assets, Current 31K USD -35.4%
Assets, Current 5.67M USD -32%
Assets 5.67M USD -32%
Accounts Payable, Current 10.8M USD +34.6%
Employee-related Liabilities, Current 770K USD +10%
Liabilities, Current 21.4M USD -32.2%
Liabilities 21.4M USD -32.2%
Retained Earnings (Accumulated Deficit) -332M USD -14.7%
Stockholders' Equity Attributable to Parent -15.7M USD +32.3%
Liabilities and Equity 5.67M USD -32%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.47M USD +53.9%
Net Cash Provided by (Used in) Financing Activities 12.8M USD +87.8%
Common Stock, Shares Authorized 175M shares +119%
Common Stock, Shares, Issued 41.6M shares +142%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6.31M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 4.95M USD -33.3%
Deferred Tax Assets, Valuation Allowance 87.3M USD +34.8%
Deferred Tax Assets, Gross 87.3M USD +34.8%
Deferred Tax Assets, Operating Loss Carryforwards 45M USD +11.2%
Additional Paid in Capital 316M USD +18.8%